Oruka Therapeutics closed at $101.41 on Nov 4, up 1.87%, 10.3% below its 52-week closing high. Volume of 791.0K shares was 0.88× its 20-day average (close to normal).
Split-adjusted performance: +26.5% over one month, +45.3% over six months, +287.2% over one year.
Short interest was 6.1M shares at the Oct 15 settlement, down 21.4% from the prior report (11.5% of float, 7.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ORKAOruka Therapeutics | $101.41 | +1.87% | +45.3% | — | — | — | $6.71B | |
| IONSIonis Pharmaceuticals | $40.15 | −0.67% | −47.8% | −40.7% | −42.8% | — | $6.67B | Compare |
| AMRXAmneal Pharmaceuticals | $19.95 | −1.29% | +46.5% | +9.9% | 7.2% | 44.2 | $6.95B | Compare |
| LGNDLigand Pharmaceuticals | $316.13 | +0.83% | +35.9% | −31.8% | −36.2% | 122.9 | $6.32B | Compare |
| MIRMMirum Pharmaceuticals | $96.97 | +11.42% | −11.9% | +39.6% | −22.0% | — | $6.30B | Compare |
| AXSMAxsome Therapeutics | $137.00 | −1.87% | −38.5% | +51.9% | −5.0% | — | $7.18B | Compare |
| KNSAKiniksa Pharmaceuticals International | $96.12 | +3.03% | +65.1% | +58.1% | 16.6% | 68.9 | $7.55B | Compare |
| RYTMRhythm Pharmaceuticals | $110.68 | +28.04% | +14.6% | +46.9% | −70.7% | — | $7.62B | Compare |
| ALKSAlkermes | $45.89 | +0.44% | +29.9% | +21.8% | 3.4% | — | $7.70B | Compare |
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
